CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a diversified oncology firm centered on growing an arsenal of next-generation therapeutics to focus on difficult-to-treat cancers and enhance high quality of life for sufferers, reported on September 30, 2022 that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted inventory items with respect to an mixture of 213,030 shares of Pyxis Oncology’s frequent inventory and inventory choices to buy an mixture of 266,290 shares of Pyxis Oncology’s frequent inventory to seventeen newly employed staff. The awards have been granted underneath the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of September 30, 2022, as an inducement materials to the brand new worker coming into employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted inventory items and inventory choices vest over 4 years, with 25% vesting on the primary anniversary of the vesting graduation date for every worker and the remaining shares vesting month-to-month over the 36-month interval thereafter, topic to continued employment with the Company via the relevant vesting dates. The inventory choices have a ten-year time period and an train worth of $1.97, the closing worth of Pyxis Oncology’s frequent inventory as reported by Nasdaq on September 30, 2022.
Pyxis Oncology is offering this data in accordance with Nasdaq Listing Rule 5635(c)(4).
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is an oncology firm centered on growing an arsenal of next-generation therapeutics to focus on difficult-to-treat cancers and enhance high quality of life for sufferers. By leveraging our absolutely built-in analysis, improvement and industrial capabilities, our professional group is effectively constructing a diversified portfolio of next-generation therapeutics. Pyxis Oncology’s therapeutic candidates are designed to instantly kill tumor cells, and to deal with the underlying pathologies created by most cancers that allow its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis Oncology has developed a broad portfolio of novel antibody-drug conjugate, or ADC, immuno-oncology, or IO, product candidates, and monoclonal antibody, or mAb, preclinical discovery applications that it’s growing as monotherapies and together with different therapies. To be taught extra about Pyxis Oncology, go to www.pyxisoncology.com.
Pyxis Oncology Contact
Pamela Connealy
Chief Financial Officer
(617) 453-3596
[email protected]
